Clinical Trial Update: Assessing the Safety and Efficacy of Full-Spectrum Medicinal Cannabis Plant Extract 0.08% THC (NTI164) in the Treatment of Rett Syndrome (RTT) [Phase 1, Phase 2]

View source ↗

Summary

Update on a Phase 1/2 clinical trial evaluating NTI164, a full-spectrum cannabis plant extract with 0.08% THC, for Rett Syndrome; the study is currently active …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rett Syndrome

Drugs mentioned

• NTI164

Snippet

Sponsor: Fenix Innovation Group | Conditions: Rett Syndrome | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING